ClinicalTrials.gg
RecruitingNCT07861425Updated Nov 17, 2026

Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs

A Phase 1 interventional study of ACE723 in Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic and Hepatocellular Carcinoma Non-Resectable, sponsored by Acepodia Biotech, Inc.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Acepodia Biotech, Inc. · Phase 1, Interventional, and Treatment

Updated Nov 17, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,312 studies in Carcinoma, Hepatocellular with a site in China — 488 open to participants now, 560 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Planned enrollment
540th of 1,035
70 · median 78
Started
2026
with 95 others
Phase 1
139 of 1,312
61 open now
Primary completion
2030-05
later than 536 of 559 live
Registered
1,305th of 1,312
by date

Among the 1,312 studies in Carcinoma, Hepatocellular with a site in China, this one is the 540th largest by planned enrollment of the 1,035 interventional ones that give a count, is one of 96 that started in 2026, is one of 139 in phase 1, reaches primary completion later than 536 of the 559 other live ones, and was the 1,305th registered.

Carcinoma, Hepatocellular

3,652 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

488 of the 1,312 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

482 more — sign in →

All 488 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,312 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

ACE723 is a dual-payload antibody drug conjugate targeting glypican-3 (GPC-3) that is under investigation for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)
  • Hepatocellular Carcinoma Metastatic
  • Hepatocellular Carcinoma Non-Resectable

Keywords

  • ACE723
  • Antibody Drug Conjugate
  • ADC
  • Hepatocellular Carcinoma
  • HCC
  • Glypican-3
  • GPC-3
04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged 18 to 75 years
  • HCC that is unresectable or
  • confirmed HCC
  • Barcelona Clinic Liver Cancer (BCLC) stage B or C
  • Presence of at least 1 per 1.1
  • Performance Score of 0 or 1
  • of at least 3 months for the dose escalation portion and of at least 6 months for the dose expansion portion
  • Adequate bone marrow reserve
  • Adequate renal function
  • Adequate hepatic function
  • (LVEF) ≥50%
  • Ability to fully understand the nature of this study
  • Agreement to requirements

Exclusion criteria

Exclusion Criteria:

  • Other types of hepatic , such as mixed cholangiocarcinoma/HCC, sarcomatoid HCC, or fibrolamellar HCC,
  • History of another malignancy within the past 5 years
  • Ascites that requires non-pharmacologic intervention (e.g., paracentesis) to maintain symptomatic control, within 6 months of screening
  • History of hepatic encephalopathy within 12 months
  • History of (non-infectious) ILD/pneumonitis
  • History of severe allergic or anaphylactic reactions to humanized monoclonal antibodies or known sensitivity or allergy to any components of ACE723.
  • History of bleeding events (including hematemesis or melena) due to esophageal and/or gastric varices within 6 months prior to screening
  • Active
  • Unresolved toxicities from prior anticancer therapy
  • active infection
  • Active syphilis infection and infection
  • Pregnancy or breast-feeding women
  • Uncontrolled intercurrent illness
  • History of known substance abuse or illicit drug use
  • Poor compliance
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    ACE723

    Drug: ACE723

Interventions

  • DrugACE723

    Intravenous Administration

06

What researchers measure

Primary outcomes

  1. Part 1: To assess the safety and tolerability of ACE723 administered at multiple ascending doses

    * Incidence of dose-limiting toxicities (DLTs) during the DLT evaluation period * Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: Up to 12 months post-last dose

  2. Part 1: To determine the maximum tolerated dose (MTD) of ACE723

    Time frame: Up to 12 months post-last dose

  3. Part 1: To determine the recommended ACE723 doses for further evaluation in the dose expansion phase

    Time frame: Up to 12 months post-last dose

  4. Part 2: To assess the safety and tolerability of ACE723 at the expansion doses

    • Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: Up to 12 months post-last dose

  5. Part 2: To determine the Recommended Phase 2 Dose (RP2D) of ACE723 for further clinical evaluation

    Time frame: Up to 12 months post-last dose

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2030, 42 months later.

Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 42 months is below that.

Counting every sponsor, half of 250 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 6, 2026
StartEst.
Nov 2026
Primary completionEst.
May 2030
CompletionEst.
May 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Nanjing Tianyinshan Hospital · Nanjing, Chinano status→Recruiting
  • Zhongshan Hospital, Fudan University · Shanghai, Chinano status→Recruiting
Nov 17, 2026
Eligibility
2 exclusion criteria edited
What changed in the criteria
Exclusion criteria
  • EditedAscites that requires non-pharmacologic intervention (e.g., paracentesis) to maintain symptomatic control, within 6 months of screening
  • EditedHistory of bleeding events (including hematemesis or melena) due to esophageal and/or gastric varices within 6 months prior to screening
Nov 17, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 2 updates
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Nanjing Tianyinshan Hospital · Nanjing, Chinano status→Recruiting
    • Zhongshan Hospital, Fudan University · Shanghai, Chinano status→Recruiting
    Eligibility 2 exclusion criteria edited
    What changed in the criteria
    Exclusion criteria
    • EditedAscites that requires non-pharmacologic intervention (e.g., paracentesis) to maintain symptomatic control, within 6 months of screening
    • EditedHistory of bleeding events (including hematemesis or melena) due to esophageal and/or gastric varices within 6 months prior to screening
  2. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861425
Lead sponsor
Acepodia Biotech, Inc.
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Nov 2026 (estimated)
Primary completion
May 2030 (estimated)
Completion
May 2030 (estimated)
Last update
Nov 17, 2026

Study contacts

Acepodia Clinical Team
Contact
clinical@acepodiabio.com
415 366 7822

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion